Back to results
Bibliographic record · Consultation and access
Artículo

Atomoxetine: toxicological aspects of a new treatment for attention deficit hyperactivity disorder in Brazil

Gabriel Christian de Farias Morais et al · Associação de Psiquiatria do Rio Grande do Sul · 2025

Open access available
Quick overview. Review the resource’s basic details, then access the content using the main button. This page shows only the information needed to identify, cite, and open the work.

Resource access

Open the content from the main option or choose another available source.

DOAJ DOAJ Articles
Entrar por DOAJ
Main access

Open access available

Recurso identificado como acceso abierto, sin confirmar automáticamente si es texto completo directo.
Open resource

Summary

Descripción general del contenido del recurso.

Abstract Objective Atomoxetine is widely used in the treatment of attention deficit hyperactivity disorder (ADHD), offering reduced risks of adverse motor effects and chemical dependence. However, its pharmacokinetic properties and toxicological risks require further exploration. This study aimed to predict the physicochemical profile, medicinal chemistry characteristics, and ADMET (absorption, distribution, metabolism, excretion, and toxicity) properties of atomoxetine using in silico web-based tools. Methods Physicochemical, medicinal chemistry, and pharmacokinetic parameters of atomoxetine were analyzed using predictive computational models. Emphasis was placed on properties that influence drug efficacy and safety, particularly in the context of ADHD treatment. Results In silico analyses revealed that atomoxetine may carry potential risks of hepatotoxicity, cardiotoxicity, neurotoxicity, nephrotoxicity, respiratory system toxicity, skin toxicity, and carcinogenicity. These predicted toxicological effects highlight the importance of further investigation into atomoxetine’s safety, especially across diverse patient populations and varying durations of treatment. Conclusion The findings from this predictive study suggest that careful monitoring of atomoxetine use is warranted in clinical settings. Furthermore, additional controlled studies are needed to develop personalized dosing protocols that account for individual variability in metabolism and toxicity response, enabling a safer and more effective use of the drug.

How to cite

Elegí el formato que necesitás y copiá la referencia al portapapeles.

APA 7

al, G. C. D. F. M. E. (2025). Atomoxetine: toxicological aspects of a new treatment for attention deficit hyperactivity disorder in Brazil. https://doi.org/10.47626/2237-6089-2024-0798

MLA

al, Gabriel Christian de Farias Morais et. "Atomoxetine: toxicological aspects of a new treatment for attention deficit hyperactivity disorder in Brazil." 2025. https://doi.org/10.47626/2237-6089-2024-0798.

Chicago

al, Gabriel Christian de Farias Morais et. 2025. "Atomoxetine: toxicological aspects of a new treatment for attention deficit hyperactivity disorder in Brazil.". https://doi.org/10.47626/2237-6089-2024-0798.

Harvard

al, G. C. D. F. M. E. 2025, Atomoxetine: toxicological aspects of a new treatment for attention deficit hyperactivity disorder in Brazil, Associação de Psiquiatria do Rio Grande do Sul, available at: https://doi.org/10.47626/2237-6089-2024-0798 [Accessed 7 Aug. 2026].

Share and print

Save the record, copy its permanent link, or print it as a PDF.

Export reference

You can export the record in common formats for use in a reference manager.

Resource details

Bibliographic information to help confirm that this is the correct material.

Title
Atomoxetine: toxicological aspects of a new treatment for attention deficit hyperactivity disorder in Brazil
Author / contributors
Gabriel Christian de Farias Morais et al
Publisher
Associação de Psiquiatria do Rio Grande do Sul
Publication year
2025
ISSN
2238-0019
ISSN
2238-0019
Language
English
Copied